NTLA
HEALTHCAREIntellia Therapeutics Inc
$13.85+0.54 (+4.06%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving NTLA Today?
No stock-specific AI insight has been generated for NTLA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$6.83$28.25
$13.85
Fundamentals
Market Cap$1.6B
P/E Ratio—
EPS$-3.81
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume—
Avg Volume (10D)—
Shares Outstanding118.9M
NTLA News
20 articles- Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 7, 2026
- Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Yahoo Finance·May 7, 2026
- Assessing Intellia Therapeutics (NTLA) Valuation After Positive Phase 3 HAELO Results And BLA Submission For Lonvo ZYahoo Finance·May 7, 2026
- Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 6, 2026
- Cathie Wood Goes Bargain Hunting: 3 Stocks She Just BoughtMotley Fool·May 6, 2026
- Intellia Therapeutics Stock Is Down Nearly 95% From Its Record Highs but Cathie Wood Keeps BuyingBarchart·May 5, 2026
- Intellia Therapeutics to Participate in Upcoming Investor ConferencesYahoo Finance·May 5, 2026
- Cathie Wood Dumps $72 Million of AMD, Doubles Down on Alphabet and MetaYahoo Finance·May 4, 2026
- Intellia Therapeutics (NTLA) Is Down 15.1% After Phase 3 lonvo-z Data And $180M Equity Raise - Has The Bull Case Changed?Yahoo Finance·May 1, 2026
- Cathie Wood Buys Tumbling Robinhood Stock, ARK Adds $30 Mil Of This StockYahoo Finance·Apr 30, 2026
- KalVista Scores $1.9 Billion Takeover Deal; Why A Key Rival Jumped TooYahoo Finance·Apr 29, 2026
- Cathie Wood Loads Up $14 Million on Alphabet Just Before EarningsYahoo Finance·Apr 29, 2026
- Intellia Therapeutics Announces Pricing of Public Offering of Common StockYahoo Finance·Apr 29, 2026
- NTLA Falls 4% Despite Strong Phase III HAE Data, Initiates Rolling BLAYahoo Finance·Apr 28, 2026
- Intellia Therapeutics Posts Phase 3 HAELO Win for lonvo-z, Begins Rolling FDA BLA FilingMarketbeat·Apr 28, 2026
- Why The Narrative Around Intellia Therapeutics (NTLA) Is Shifting After FDA Hold ResolutionsYahoo Finance·Apr 28, 2026
- Intellia Successfully Edited Genes Inside The Body. Why Shares Aren't Flying.Yahoo Finance·Apr 27, 2026
- Intellia Announces Proposed Public Offering of Common StockYahoo Finance·Apr 27, 2026
- Intellia Therapeutics Pops on CRISPR Trial Success. Does That Make NTLA Stock a Buy?Barchart·Apr 27, 2026
- Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire Inc.·Apr 3, 2026
All 20 articles loaded
Price Data
Open$0.00
Previous Close$13.31
Day High$0.00
Day Low$0.00
52 Week High$28.25
52 Week Low$6.83
52-Week Range
$6.83$28.25
$13.85
Fundamentals
Market Cap$1.6B
P/E Ratio—
EPS$-3.81
Dividend Yield—
Dividend / Share—
ROE-0.5%
Profit Margin—
Debt / Equity—
Trading
Volume—
Avg Volume (10D)—
Shares Outstanding118.9M
About Intellia Therapeutics Inc
Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—